CN1447809A - 神经变性疾病的预防和治疗药物 - Google Patents
神经变性疾病的预防和治疗药物 Download PDFInfo
- Publication number
- CN1447809A CN1447809A CN01814283A CN01814283A CN1447809A CN 1447809 A CN1447809 A CN 1447809A CN 01814283 A CN01814283 A CN 01814283A CN 01814283 A CN01814283 A CN 01814283A CN 1447809 A CN1447809 A CN 1447809A
- Authority
- CN
- China
- Prior art keywords
- oxadiazole
- naphthyridine
- ketone
- neurodegenerative disease
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
实验组 | 动物序号 | 空泡形成 | |||||
切片序号 | 平均(/切片) | ||||||
1 | 2 | 3 | 4 | ||||
个体 | 组 | ||||||
无处理对照组 | 01M01 | 0 | 0 | 0 | 0 | 0.0 | 0.0 |
01M02 | 0 | 0 | 0 | 0 | 0.0 | ||
01M03 | 0 | 0 | 0 | 0 | 0.0 | ||
MK-8011mg/kgs.c.5h组 | 02M01 | 41 | 50 | 34 | 19 | 36.0 | 30.8 |
02M02 | 23 | 39 | 42 | 40 | 36.0 | ||
02M03 | 26 | 24 | 14 | 17 | 20.3 | ||
化合物A1mg/kg p.o.+MK-8011mg/kg s.c.5h组 | 03M01 | 0 | 0 | 0 | 0 | 0.0 | 43 |
03M02 | 20 | 12 | 10 | 5 | 11.8 | ||
03M03 | 0 | 0 | 2 | 2 | 1.0 |
Claims (12)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP185814/00 | 2000-06-21 | ||
JP2000185814 | 2000-06-21 | ||
JP185814/2000 | 2000-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1447809A true CN1447809A (zh) | 2003-10-08 |
CN100354274C CN100354274C (zh) | 2007-12-12 |
Family
ID=18686074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018142834A Expired - Fee Related CN100354274C (zh) | 2000-06-21 | 2001-06-12 | 神经变性疾病的预防和治疗药物 |
Country Status (19)
Country | Link |
---|---|
US (1) | US6743803B2 (zh) |
EP (1) | EP1295883A4 (zh) |
KR (1) | KR20030010740A (zh) |
CN (1) | CN100354274C (zh) |
AU (2) | AU6274101A (zh) |
BR (1) | BR0111799A (zh) |
CA (1) | CA2412199A1 (zh) |
CZ (1) | CZ20024153A3 (zh) |
EE (1) | EE04941B1 (zh) |
HU (1) | HUP0301319A3 (zh) |
IL (2) | IL153439A0 (zh) |
MX (1) | MXPA02012599A (zh) |
NO (1) | NO20026148L (zh) |
NZ (1) | NZ523189A (zh) |
PL (1) | PL200537B1 (zh) |
RU (1) | RU2258506C2 (zh) |
SK (1) | SK17682002A3 (zh) |
TW (1) | TWI298068B (zh) |
WO (1) | WO2001098300A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114401711A (zh) * | 2019-07-18 | 2022-04-26 | 阿巴克西斯治疗公司 | 1,2,4-噁二唑衍生物的固体制剂 |
CN114401711B (zh) * | 2019-07-18 | 2024-06-04 | 阿巴克西斯治疗公司 | 1,2,4-噁二唑衍生物的固体制剂 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
WO2010002451A1 (en) * | 2008-07-01 | 2010-01-07 | Concert Pharmaceuticals, Inc. | Naphthyridin derivatives |
JP6551671B2 (ja) * | 2015-08-11 | 2019-07-31 | 国立大学法人 熊本大学 | アルツハイマー治療薬 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2683818B1 (fr) * | 1991-11-14 | 1993-12-31 | Adir Cie | Nouveaux derives de 3-sulfonylamino-2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
JPH09291034A (ja) | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
TW486479B (en) * | 1997-07-15 | 2002-05-11 | Dainippon Pharmaceutical Co | 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivatives |
AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
IL146871A0 (en) | 1999-06-02 | 2002-08-14 | Nps Pharma Inc | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
-
2001
- 2001-06-06 TW TW090113656A patent/TWI298068B/zh not_active IP Right Cessation
- 2001-06-12 IL IL15343901A patent/IL153439A0/xx active IP Right Grant
- 2001-06-12 NZ NZ523189A patent/NZ523189A/en unknown
- 2001-06-12 US US10/311,932 patent/US6743803B2/en not_active Expired - Fee Related
- 2001-06-12 PL PL363869A patent/PL200537B1/pl not_active IP Right Cessation
- 2001-06-12 BR BR0111799-8A patent/BR0111799A/pt not_active Application Discontinuation
- 2001-06-12 RU RU2003101405/04A patent/RU2258506C2/ru not_active IP Right Cessation
- 2001-06-12 CA CA002412199A patent/CA2412199A1/en not_active Abandoned
- 2001-06-12 EP EP01936958A patent/EP1295883A4/en not_active Withdrawn
- 2001-06-12 CZ CZ20024153A patent/CZ20024153A3/cs unknown
- 2001-06-12 AU AU6274101A patent/AU6274101A/xx active Pending
- 2001-06-12 MX MXPA02012599A patent/MXPA02012599A/es active IP Right Grant
- 2001-06-12 SK SK1768-2002A patent/SK17682002A3/sk unknown
- 2001-06-12 HU HU0301319A patent/HUP0301319A3/hu unknown
- 2001-06-12 AU AU2001262741A patent/AU2001262741B2/en not_active Ceased
- 2001-06-12 CN CNB018142834A patent/CN100354274C/zh not_active Expired - Fee Related
- 2001-06-12 WO PCT/JP2001/004934 patent/WO2001098300A1/ja active IP Right Grant
- 2001-06-12 EE EEP200200698A patent/EE04941B1/xx not_active IP Right Cessation
- 2001-06-12 KR KR1020027017221A patent/KR20030010740A/ko not_active Application Discontinuation
-
2002
- 2002-12-15 IL IL153439A patent/IL153439A/en not_active IP Right Cessation
- 2002-12-20 NO NO20026148A patent/NO20026148L/no not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114401711A (zh) * | 2019-07-18 | 2022-04-26 | 阿巴克西斯治疗公司 | 1,2,4-噁二唑衍生物的固体制剂 |
CN114401711B (zh) * | 2019-07-18 | 2024-06-04 | 阿巴克西斯治疗公司 | 1,2,4-噁二唑衍生物的固体制剂 |
Also Published As
Publication number | Publication date |
---|---|
NO20026148D0 (no) | 2002-12-20 |
NO20026148L (no) | 2003-02-20 |
NZ523189A (en) | 2004-08-27 |
IL153439A0 (en) | 2003-07-06 |
BR0111799A (pt) | 2003-05-27 |
PL200537B1 (pl) | 2009-01-30 |
AU2001262741B2 (en) | 2005-07-07 |
SK17682002A3 (sk) | 2003-08-05 |
MXPA02012599A (es) | 2003-05-14 |
TWI298068B (en) | 2008-06-21 |
EP1295883A4 (en) | 2003-06-11 |
EP1295883A1 (en) | 2003-03-26 |
IL153439A (en) | 2007-07-24 |
HUP0301319A2 (hu) | 2003-09-29 |
CZ20024153A3 (cs) | 2003-06-18 |
KR20030010740A (ko) | 2003-02-05 |
US20030166673A1 (en) | 2003-09-04 |
AU6274101A (en) | 2002-01-02 |
EE200200698A (et) | 2004-08-16 |
CA2412199A1 (en) | 2001-12-27 |
RU2258506C2 (ru) | 2005-08-20 |
EE04941B1 (et) | 2007-12-17 |
US6743803B2 (en) | 2004-06-01 |
CN100354274C (zh) | 2007-12-12 |
PL363869A1 (en) | 2004-11-29 |
HUP0301319A3 (en) | 2008-06-30 |
WO2001098300A1 (fr) | 2001-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10844061B2 (en) | Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous system | |
JP2005518411A (ja) | 中枢神経系の障害を治療する製薬組成物及び方法 | |
JP2022523700A (ja) | 心理性、認知性、行動性、および/または気分性の障害を処置するための方法、ならびに5ht受容体アゴニストを含む組成物 | |
JP2021075566A (ja) | 新規方法 | |
JPH05194227A (ja) | 薬 剤 | |
CN102743382B (zh) | 刺激神经形成和抑制神经元变性的方法和组合物 | |
JP2014196328A (ja) | ニコチン性アセチルコリンα7受容体アゴニストの組合せ剤 | |
CN105461694A (zh) | 取代的杂芳基化合物及其组合物和用途 | |
CN100388918C (zh) | 含有氮杂环丁烷衍生物的药物组合物 | |
KR20220029744A (ko) | 신규 방법 | |
CN107787227A (zh) | Nut中线癌的治疗 | |
CN100354274C (zh) | 神经变性疾病的预防和治疗药物 | |
KR20190110457A (ko) | 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법 | |
CN113905737A (zh) | 治疗神经性疼痛的方法 | |
TWI289060B (en) | Pharmaceutical composition for improving the recovery of post-stroke patients | |
JP2012500248A (ja) | 不安障害の治療 | |
AU2018379448A1 (en) | Pharmaceutical formulation | |
EA018788B1 (ru) | Лиганд с широким спектром фармакологической активности и его применение | |
CN1418099A (zh) | 用于治疗肌纤维疼痛和慢性疲劳综合征的精选化合物 | |
KR101515222B1 (ko) | 티아넵틴 나트륨 함유 제어방출성 경구용 단층 제제 및 이의 제조방법 | |
US3126319A (en) | Method for the potentiation of anti- | |
JPH07502517A (ja) | 精神病の治療のためのアリールインドールの使用 | |
CN1758912A (zh) | 药物·物质依赖治疗药 | |
WO2005049041A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of anxiety disorders | |
HU221313B (en) | Synergetic analgesic pharmaceutical composition and process for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NIPPO SUMITOMO PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: DAINIPPON PHARMACEUTICAL CO., LTD. Effective date: 20060303 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060303 Address after: Osaka City, Osaka of Japan Applicant after: Dainippon Sumitomo Pharma Co., Ltd. Address before: Osaka City, Osaka of Japan Applicant before: Dainippon Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071212 |